CGTX
Cognition
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
CGTX Profile
Cognition Therapeutics, Inc.
A biopharmaceutical company focused on developing innovative therapeutics for neurological and psychiatric disorders
2500 Westchester Ave., Purchase, NY 10577
--
Cognition Therapeutics, Inc., was incorporated under the laws of the State of Delaware on August 21, 2007. The Company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule therapies for age-related degenerative and central nervous system diseases (CNS) and the retina. There are currently limited therapies available to treat diseases, and there are no approved therapies or treatments for many diseases. The company's goal is to develop disease-modifying treatments for patients with degenerative diseases by initially leveraging its expertise in β-2 (SIGMA-2) receptors.